<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442985</url>
  </required_header>
  <id_info>
    <org_study_id>PVO-2A-201</org_study_id>
    <nct_id>NCT03442985</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Palovarotene for the Treatment of MO</brief_title>
  <acronym>MO-Ped</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clementia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clementia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study comparing the safety and
      efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease
      progression in pediatric subjects with multiple osteochondromas (MO).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple osteochondromas is a rare condition where children develop multiple benign
      cartilage-capped bony tumors called osteochondromas on bones throughout the body, resulting
      in pain, deformity, limb length discrepancy, disability, and eventually arthritis and
      possible malignancy. The primary objective is to compare the efficacy of two dosage regimens
      of palovarotene with placebo to prevent the formation of new osteochondromas in pediatric MO
      subjects with exostosin 1 or exostosin 2 gene mutations. Osteochondroma formation will be
      assessed by whole body magnetic resonance imaging (MRI). Secondary efficacy objectives are to
      compare the effect of palovarotene on the volume of osteochondromas as assessed by MRI; and
      on the annualized rate of new or worsening deformities and MO-related surgeries. The overall
      safety of palovarotene and the effects of palovarotene on linear growth, bone growth plates,
      bone mineral density, quality of life, and pain due to osteochondromas will also be studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of new osteochondromas</measure>
    <time_frame>Month 24</time_frame>
    <description>The annualized rate of new osteochondromas as assessed by whole body magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total volume of osteochondromas</measure>
    <time_frame>Months 12 and 24/end-of-treatment (EOT)</time_frame>
    <description>The change from baseline in the total volume of osteochondromas as assessed by whole body MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of new or worsening deformities</measure>
    <time_frame>Months 12 and 24/EOT</time_frame>
    <description>The annualized rate of new or worsening deformities as assessed by radiographic imaging of both upper and lower limbs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of MO-related surgeries</measure>
    <time_frame>Months 12 and 24/EOT</time_frame>
    <description>The annualized rate of MO-related surgeries. Surgeries include surgical excisions of a symptomatic osteochondroma and surgical procedures to correct a joint deformities or functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palovarotene area under the concentration-time curve (AUC)</measure>
    <time_frame>Month 1</time_frame>
    <description>Determination of AUC at steady-state assessed during treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Palovarotene: Monitoring of adverse events</measure>
    <time_frame>Study Day 1; and from Months 1 to 36/ET at every subject contact</time_frame>
    <description>Monitoring of adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Annualized rate of new or worsening functional limitations</measure>
    <time_frame>Months 12 and 24/EOT</time_frame>
    <description>The annualized rate of new or worsening functional limitations. Functional limitations are defined as restrictions in joint range of motion.</description>
  </other_outcome>
  <other_outcome>
    <measure>PedsQL</measure>
    <time_frame>Months 6, 12, 18, and 24/EOT</time_frame>
    <description>The Pediatric Quality of Life Inventory (PedsQL, version 4.0) questionnaire to assess quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>PROMIS Global Health Scale</measure>
    <time_frame>Months 6, 12, 18, and 24/EOT</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference pediatric item bank to assess the effect of pain on daily activities.</description>
  </other_outcome>
  <other_outcome>
    <measure>FPS-R</measure>
    <time_frame>Months 6, 12, 18, and 24/EOT</time_frame>
    <description>The Faces Pain Scale - Revised (FPS-R) to assess pain intensity.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Exostoses, Multiple Hereditary</condition>
  <arm_group>
    <arm_group_label>Palovarotene 2.5 mg daily regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Palovarotene 5.0 mg daily regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palovarotene 2.5 mg</intervention_name>
    <description>Subjects will receive a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.</description>
    <arm_group_label>Palovarotene 2.5 mg daily regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palovarotene 5.0 mg</intervention_name>
    <description>Subjects will receive a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.</description>
    <arm_group_label>Palovarotene 5.0 mg daily regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo, once daily, for up to 24 months.</description>
    <arm_group_label>Placebo regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written, signed, and dated informed subject/parent consent and age-appropriate assent
             (performed according to local regulations).

          -  A clinical diagnosis of MO with exostosin 1 or 2 gene mutations.

          -  Male or female from 2 to 14 years of age.

          -  Female subjects must be premenarchal at screening.

          -  A bone age at screening of 14 years or less.

          -  Symptomatic MO, defined as a new or enlarged osteochondroma that occurred in the
             preceding 12 months, a painful osteochondroma, a skeletal deformity, a joint
             limitation, or prior surgery for a MO-related complication.

          -  The ability to undergo whole body MRI without general anesthesia requiring intubation.

          -  Abstinent or using two highly effective forms of birth control.

        Key Exclusion Criteria:

          -  Weight under 10 kg.

          -  Other syndromic conditions such as Langer-Giedion or Potocki-Shaffer.

          -  Any subject with neurologic signs suggestive of spinal cord impingement.

          -  Concomitant medications that are strong inhibitors or inducers of cytochrome P450 3A4
             activity.

          -  Amylase or lipase &gt;2 times the above the upper limit of normal (&gt;2×ULN) or with a
             history of chronic pancreatitis.

          -  Elevated aspartate aminotransferase or alanine aminotransferase above 2.5×ULN.

          -  Any surgical implant that is contraindicated for MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clementia Call Center (US/Canada Only)</last_name>
    <phone>1-800-750-8710</phone>
    <email>ClinicalTrials@clementiapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paley Orthopedic and Spine Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>330407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troy Rand</last_name>
      <phone>561-531-1553</phone>
      <email>trand@paleyinstitute.org</email>
    </contact>
    <investigator>
      <last_name>David Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children — Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19410-4160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Solomon (Praveen)</last_name>
      <phone>215-430-4081</phone>
      <email>ssamuel@shrinenet.org</email>
    </contact>
    <investigator>
      <last_name>Bethany Lipa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mhecoalition.org/</url>
    <description>MHE Coalition</description>
  </link>
  <link>
    <url>http://www.mherf.org/</url>
    <description>MHE Research Foundation</description>
  </link>
  <reference>
    <citation>Inubushi T, Lemire I, Irie F, Yamaguchi Y. Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses. J Bone Miner Res. 2018 Apr;33(4):658-666. doi: 10.1002/jbmr.3341. Epub 2017 Nov 30.</citation>
    <PMID>29120519</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple osteochondromas</keyword>
  <keyword>Osteochondroma</keyword>
  <keyword>Palovarotene</keyword>
  <keyword>Hereditary multiple exostoses</keyword>
  <keyword>HME</keyword>
  <keyword>MO</keyword>
  <keyword>Retinoic acid receptor gamma agonist</keyword>
  <keyword>Retinoic acid receptor agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exostoses</mesh_term>
    <mesh_term>Osteophyte</mesh_term>
    <mesh_term>Osteochondroma</mesh_term>
    <mesh_term>Exostoses, Multiple Hereditary</mesh_term>
    <mesh_term>Osteochondromatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

